These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15127675)

  • 21. DA agonists -- non-ergot derivatives: piribedil: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S90-2. PubMed ID: 12211147
    [No Abstract]   [Full Text] [Related]  

  • 22. Problematic gambling on dopamine agonists: Not such a rarity.
    Grosset KA; Macphee G; Pal G; Stewart D; Watt A; Davie J; Grosset DG
    Mov Disord; 2006 Dec; 21(12):2206-8. PubMed ID: 17013907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide.
    Jiménez-Jiménez FJ; López-Alvarez J; Sánchez-Chapado M; Montero E; Miquel J; Sierra A; Gutiérrez F
    Clin Neuropharmacol; 1995 Jun; 18(3):277-9. PubMed ID: 8635187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine agonists in the treatment of Parkinson's disease.
    Bonuccelli U; Pavese N
    Expert Rev Neurother; 2006 Jan; 6(1):81-9. PubMed ID: 16466315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.
    Marek K; Jennings D; Seibyl J
    Ann Neurol; 2003; 53 Suppl 3():S160-6; discussion S166-9. PubMed ID: 12666107
    [No Abstract]   [Full Text] [Related]  

  • 27. Pergolide in Parkinson's disease: time for a change?
    Grosset KA; Grosset DG
    Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636
    [No Abstract]   [Full Text] [Related]  

  • 28. Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists.
    Albanese A; Colosimo C
    Acta Neurol Scand; 2003 May; 107(5):349-55. PubMed ID: 12713527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease.
    Obeso JA; Grandas F; Herrero MT; Horowski R
    Eur J Neurosci; 1994 Jun; 6(6):889-97. PubMed ID: 7952277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine agonist withdrawal syndrome in Parkinson's disease.
    Solla P; Fasano A; Cannas A; Marrosu F
    J Neurol Sci; 2017 Nov; 382():47-48. PubMed ID: 29111017
    [No Abstract]   [Full Text] [Related]  

  • 31. Sleep attacks in Parkinson's disease.
    Pirker W; Happe S
    Lancet; 2000 Aug; 356(9229):597-8. PubMed ID: 10950264
    [No Abstract]   [Full Text] [Related]  

  • 32. DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S83-9. PubMed ID: 12211146
    [No Abstract]   [Full Text] [Related]  

  • 33. DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S79-82. PubMed ID: 12211145
    [No Abstract]   [Full Text] [Related]  

  • 34. [Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review].
    Bode M
    Ugeskr Laeger; 2009 Oct; 171(41):2996-9. PubMed ID: 19814927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.
    Kenney C; Jankovic J
    Expert Opin Pharmacother; 2007 Jun; 8(9):1329-35. PubMed ID: 17563266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature.
    Thobois S
    Clin Ther; 2006 Jan; 28(1):1-12. PubMed ID: 16490575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sleep attacks and dopamine agonists for Parkinson's disease: what is currently known?
    Zesiewicz TA; Hauser RA
    CNS Drugs; 2003; 17(8):593-600. PubMed ID: 12775195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.
    Solla P; Cannas A; Marrosu MG; Marrosu F
    Parkinsonism Relat Disord; 2015 Nov; 21(11):1383-4. PubMed ID: 26453388
    [No Abstract]   [Full Text] [Related]  

  • 39. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.